Interius

Interius company information, Employees & Contact Information

Explore related pages

Related company profiles:

Welcome to INTERIUS! We are a leading interior design firm, supported by the Skandhanshi Group. INTERIUS is known for its commitment to customer satisfaction, innovative designs, & exceptional post-sales service. The INTERIUS Experience Center is a hub for creating your dream space, offering thousands of quality-tested interiors, decor, and furniture elements. Our interior services in Hyderabad, Kurnool, Anantapur, Bengaluru, & Ballari provide a transformative journey to elevate your space into a realm of timeless elegance & style. With industry experts guiding you, you can create your ideal environment. INTERIUS is a center that offers a unique product exploration experience, allowing users to unleash their creativity & transform their spaces, redefining the art of interior design in the industry. INTERIUS merges your vision and expertise in interior design, ensuring transformative experiences by pushing boundaries & blending your vision with our expertise.

Company Details

Employees
61
Founded
-
Address
Skandhanshi Empire Building, Door, No: 50/727-Skn-3f, Beside Cn Hospital, Gooty Road,india
Industry
Interior Design
NAICS
Interior Design Services
HQ
Kurnool , Hyderabad , Bangalore, Andhra Pradesh
Looking for a particular Interius employee's phone or email?

Interius Questions

News

Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m - Pharmaceutical Technology

Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m Pharmaceutical Technology

Kite's Acquisition of Interius: A New Era for CAR-T in Philly - BioBuzz

Kite's Acquisition of Interius: A New Era for CAR-T in Philly BioBuzz

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius - BioPharma Dive

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius BioPharma Dive

Kite acquires Interius to develop in vivo cell therapies - BioProcess International

Kite acquires Interius to develop in vivo cell therapies BioProcess International

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million - Pharmaceutical Executive

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million Pharmaceutical Executive

Kite to buy Interius for $350 million - The Pharma Letter

Kite to buy Interius for $350 million The Pharma Letter

Penn biotech spin-out Interius acquired in $350 million deal - The Daily Pennsylvanian

Penn biotech spin-out Interius acquired in $350 million deal The Daily Pennsylvanian

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform - Business Wire

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform Business Wire

Gilead unit to acquire cell therapy developer Interius for $350 million - Reuters

Gilead unit to acquire cell therapy developer Interius for $350 million Reuters

Gilead to buy off-the-shelf CAR-T pioneer Interius for $350M - FirstWord Pharma

Gilead to buy off-the-shelf CAR-T pioneer Interius for $350M FirstWord Pharma

Gilead's Kite sails into in vivo CAR-T space with $350M Interius buyout - Fierce Biotech

Gilead's Kite sails into in vivo CAR-T space with $350M Interius buyout Fierce Biotech

Gilead buys in vivo cell therapy firm Interius for $350m - pharmaphorum

Gilead buys in vivo cell therapy firm Interius for $350m pharmaphorum

Gilead’s Kite to acquire Interius BioTherapeutics for $350 million - Investing.com

Gilead’s Kite to acquire Interius BioTherapeutics for $350 million Investing.com

California company to purchase Interius BioTherapeutics - Pennsylvania Business Report -

California company to purchase Interius BioTherapeutics Pennsylvania Business Report -

Gilead unit to acquire cell therapy developer Interius for $350 million - PharmaLive

Gilead unit to acquire cell therapy developer Interius for $350 million PharmaLive

Kite to Acquire Philadelphia-based Interius BioTherapeutics for In Vivo CAR T Therapy Platform - BioBuzz

Kite to Acquire Philadelphia-based Interius BioTherapeutics for In Vivo CAR T Therapy Platform BioBuzz

Gilead's (GILD) Kite Acquires Interius for $350 Million - GuruFocus

Gilead's (GILD) Kite Acquires Interius for $350 Million GuruFocus

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Plat - GuruFocus

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Plat GuruFocus

The Rise of the CAR-T Corridor: How Philadelphia and Maryland Are Shaping the Future of Cell Therapy - BioBuzz

The Rise of the CAR-T Corridor: How Philadelphia and Maryland Are Shaping the Future of Cell Therapy BioBuzz

Interius BioTherapeutics In Vivo CAR Therapy INT2104 Cleared for Phase 1 Clinical Trial in B-cell Malignancies Australia - CGTLive®

Interius BioTherapeutics In Vivo CAR Therapy INT2104 Cleared for Phase 1 Clinical Trial in B-cell Malignancies Australia CGTLive®

M&A analysis: Genmab bucks the bargain basement trend - Oncology Pipeline

M&A analysis: Genmab bucks the bargain basement trend Oncology Pipeline

Kite To Buy Interius BioTherapeutics In $350 Million Deal - Pulse 2.0

Kite To Buy Interius BioTherapeutics In $350 Million Deal Pulse 2.0

Interius BioTherapeutics Doses First Patient with in vivo - GlobeNewswire

Interius BioTherapeutics Doses First Patient with in vivo GlobeNewswire

Gilead's Kite erodes $2.3B off-the-shelf cell therapy deal with Shoreline - Fierce Biotech

Gilead's Kite erodes $2.3B off-the-shelf cell therapy deal with Shoreline Fierce Biotech

Gilead's Kite division snaps up Interius BioTherapeutics to advance cancer treatment technology - The Business Journals

Gilead's Kite division snaps up Interius BioTherapeutics to advance cancer treatment technology The Business Journals

Gilead’s Kite Is Latest To Enter In Vivo CAR-T Space With Interius Buy - Citeline News & Insights

Gilead’s Kite Is Latest To Enter In Vivo CAR-T Space With Interius Buy Citeline News & Insights

First Patient Dosed with In Vivo Gene Therapy for CAR T - Inside Precision Medicine

First Patient Dosed with In Vivo Gene Therapy for CAR T Inside Precision Medicine

The in vivo revolution: How Interius, Umoja, and Vyriad are transforming CAR-T cell therapy - Labiotech.eu

The in vivo revolution: How Interius, Umoja, and Vyriad are transforming CAR-T cell therapy Labiotech.eu

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? - TradingView

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? TradingView

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy - Benzinga

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy Benzinga

A faster, simpler, cheaper cancer cell therapy is about to be tested in humans - statnews.com

A faster, simpler, cheaper cancer cell therapy is about to be tested in humans statnews.com

Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia - BioSpace

Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia BioSpace

In vivo Car-T heads for the clinic, but it’s not Sana’s | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

In vivo Car-T heads for the clinic, but it’s not Sana’s | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

In vivo CAR T cells move into clinical trials - Nature

In vivo CAR T cells move into clinical trials Nature

Lilly’s obesity drug looks more potent than Novo’s in observational study - statnews.com

Lilly’s obesity drug looks more potent than Novo’s in observational study statnews.com

10 Best Growth Stocks to Buy for the Next 2 Years - Insider Monkey

10 Best Growth Stocks to Buy for the Next 2 Years Insider Monkey

Ensoma and Interius BioTherapeutics: in vivo veritas - Nature

Ensoma and Interius BioTherapeutics: in vivo veritas Nature

Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies - PR Newswire

Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies PR Newswire

NextUp: The Philly Biotech Company Developing an In Vivo Approach to CAR T-Cell Therapy - Philadelphia Magazine

NextUp: The Philly Biotech Company Developing an In Vivo Approach to CAR T-Cell Therapy Philadelphia Magazine

Top Interius Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant